428 related articles for article (PubMed ID: 22510451)
1. Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis.
Gregersen JW; Kristensen T; Krag SR; Birn H; Ivarsen P
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S39-47. PubMed ID: 22510451
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear.
Walsh M; Casian A; Flossmann O; Westman K; Höglund P; Pusey C; Jayne DR;
Kidney Int; 2013 Aug; 84(2):397-402. PubMed ID: 23615499
[TBL] [Abstract][Full Text] [Related]
3. The relation between histopathological classification and renal outcome, ANCA subtype and treatment regimens in ANCA-associated vasculitis.
Kristensen T; Gregersen JW; Krag SR; Ivarsen P
Clin Exp Rheumatol; 2016; 34(3 Suppl 97):S105-10. PubMed ID: 27241586
[TBL] [Abstract][Full Text] [Related]
4. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
[TBL] [Abstract][Full Text] [Related]
7. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
8. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
[TBL] [Abstract][Full Text] [Related]
9. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Karras A; Pagnoux C; Haubitz M; Groot K; Puechal X; Tervaert JWC; Segelmark M; Guillevin L; Jayne D;
Ann Rheum Dis; 2017 Oct; 76(10):1662-1668. PubMed ID: 28546260
[TBL] [Abstract][Full Text] [Related]
10. ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study.
Andreiana I; Stancu S; Avram A; Taran L; Mircescu G
BMC Nephrol; 2015 Jun; 16():90. PubMed ID: 26123651
[TBL] [Abstract][Full Text] [Related]
11. Double Filtration Plasmapheresis in the Treatment of Antineutrophil Cytoplasmic Autoantibody Associated Vasculitis With Severe Renal Failure: A Preliminary Study of 15 Patients.
Chen Y; Yang L; Li K; Liu Z; Gong D; Zhang H; Liu Z; Hu W
Ther Apher Dial; 2016 Apr; 20(2):183-8. PubMed ID: 26948291
[TBL] [Abstract][Full Text] [Related]
12. Renal vasculitis presenting with acute kidney injury.
Villacorta J; Diaz-Crespo F; Acevedo M; Cavero T; Guerrero C; Praga M; Fernandez-Juarez G
Rheumatol Int; 2017 Jun; 37(6):1035-1041. PubMed ID: 28289874
[TBL] [Abstract][Full Text] [Related]
13. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
[TBL] [Abstract][Full Text] [Related]
14. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.
McAdoo SP; Tanna A; Hrušková Z; Holm L; Weiner M; Arulkumaran N; Kang A; Satrapová V; Levy J; Ohlsson S; Tesar V; Segelmark M; Pusey CD
Kidney Int; 2017 Sep; 92(3):693-702. PubMed ID: 28506760
[TBL] [Abstract][Full Text] [Related]
15. Double Filtration Plasmapheresis in the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Dysfunction.
Cheng L; Tang YQ; Yi J; Ren Q; Yang XY; Gou SJ; Zhang L; Fu P
Blood Purif; 2020; 49(6):713-722. PubMed ID: 32294643
[TBL] [Abstract][Full Text] [Related]
16. Double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody could predict end-stage renal disease in ANCA-associated vasculitis: a monocentric pilot study.
Yoo BW; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
Clin Rheumatol; 2020 Mar; 39(3):831-840. PubMed ID: 31802348
[TBL] [Abstract][Full Text] [Related]
17. A case of anti-neutrophil cytoplasmic antibody-associated vasculitis with anti-glomerular basement membrane antibodies that was successfully treated with mizoribine as a safe and effective remission maintenance therapy with prednisolone and plasma exchange.
Ikeda Y; Fukunari K; Uchiumi S; Awanami Y; Kanaya A; Matsumoto K; Fukuda M; Takashima T; Miyazono M; Ikeda Y
CEN Case Rep; 2020 Feb; 9(1):42-47. PubMed ID: 31612361
[TBL] [Abstract][Full Text] [Related]
18. Plasmapheresis rescue therapy in progressive systemic ANCA-associated vasculitis: single-center results of stepwise escalation of immunosuppression.
de Joode AA; Sanders JS; Smid WM; Stegeman CA
J Clin Apher; 2014 Oct; 29(5):266-72. PubMed ID: 24497412
[TBL] [Abstract][Full Text] [Related]
19. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Walsh M; Merkel PA; Peh CA; Szpirt WM; Puéchal X; Fujimoto S; Hawley CM; Khalidi N; Floßmann O; Wald R; Girard LP; Levin A; Gregorini G; Harper L; Clark WF; Pagnoux C; Specks U; Smyth L; Tesar V; Ito-Ihara T; de Zoysa JR; Szczeklik W; Flores-Suárez LF; Carette S; Guillevin L; Pusey CD; Casian AL; Brezina B; Mazzetti A; McAlear CA; Broadhurst E; Reidlinger D; Mehta S; Ives N; Jayne DRW;
N Engl J Med; 2020 Feb; 382(7):622-631. PubMed ID: 32053298
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study.
Frausová D; Hrušková Z; Lánská V; Lachmanová J; Tesař V
Arthritis Res Ther; 2016 Jul; 18():168. PubMed ID: 27412443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
